ArticlePLoS computational biology2006
The role of compensatory mutations in the emergence of drug resistance.
Article in PLoS computational biology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review to identify research gaps in studies modeling MenB vaccinations against Neisseria infections.PloS one · 2025Pooled it
- Population-level mathematical modeling of antimicrobial resistance: a systematic review.BMC medicine · 2019Pooled it
- No evidence of multidrug-resistantMicrobiology spectrum · 2025Observational
- Epistasis-mediated compensatory evolution in a fitness landscape with adaptational tradeoffs.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- Occurrence, Antimicrobial Resistance, and Virulence Profiles ofInternational journal of microbiology · 2024Article
- Recombination-mediated dissemination of Methicillin-resistant S. aureus clonal complex 1 in the Egyptian health care settings.Annals of clinical microbiology and antimicrobials · 2023Article
- Discrepancy in the transmissibility of multidrug-resistantEmerging microbes & infections · 2023Article
- Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Transcontinental spread and evolution of Mycobacterium tuberculosis W148 European/Russian clade toward extensively drug resistant tuberculosis.Nature communications · 2022Article
- Balancing the Virulence and Antimicrobial Resistance in VISA DAP-R CA-MRSA Superbug.Antibiotics (Basel, Switzerland) · 2022Article
- Reversion is most likely under high mutation supply when compensatory mutations do not fully restore fitness costs.G3 (Bethesda, Md.) · 2022Article
- Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.Microbiology spectrum · 2022Article
- Alterations in molecular response of Mycobacterium tuberculosis against anti-tuberculosis drugs.Molecular biology reports · 2022Review
- Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations.Computational and structural biotechnology journal · 2022Article
- Adaptive value of foot-and-mouth disease virus capsid substitutions with opposite effects on particle acid stability.Scientific reports · 2021Article
- Adaptation and compensation in a bacterial gene regulatory network evolving under antibiotic selection.eLife · 2021Article
- An evolution-based high-fidelity method of epistasis measurement: Theory and application to influenza.PLoS pathogens · 2021Article
- A Model to Investigate the Impact of Farm Practice on Antimicrobial Resistance in UK Dairy Farms.Bulletin of mathematical biology · 2021Article
- COVTree: Coevolution in OVerlapped sequences by Tree analysis server.Nucleic acids research · 2020Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogens that evolve resistance to drugs usually have reduced fitness. However, mutations that largely compensate for this reduction in fitness often arise. We investigate how these compensatory mutations affect population-wide resistance emergence as a function of drug treatment. Using a model of gonorrhea transmission dynamics, we obtain generally applicable, qualitative results that show how compensatory mutations lead to more likely and faster resistance emergence. We further show that resistance emergence depends on the level of drug use in a strongly nonlinear fashion. We also discuss what data need to be obtained to allow future quantitative predictions of resistance emergence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.